Background: Cost-effectiveness analyses of clinical preventive services are a potential
means to aid public health resource allocation. Cost-utility analysis (CUA) is a specific form …

Background: The past decade, medical technology assessment focused on cost‐
effectiveness analysis, yet there is an increasing need to consider equity implications of …

Objectives Cancer diagnoses at later stages are associated with a decrease in health-
related quality of life (HRQOL). Health state utility values (HSUVs) reflect preference-based …

Measuring health-related quality of life in patients with cancer has focused primarily on the
development of reliable and valid instruments (questionnaires), and on the effect of …

Quality-adjusted survival as a measure of the effectiveness of medical interventions captures
the tradeoffs between length and quality of life that are often involved in choosing between …

Objective. Analysts performing cost-effectiveness analyses often do not have the resources
to gather original quality-of-life (QOL) weights. Furthermore, variability in QOL for the same …

Cost-effectiveness analysis (CEA) is the main way that economic evaluations are carried out
in the health care field. However, CEA has limited validity in deciding whether any health …

Objectives The Canadian Agency for Drugs and Technologies in Health (CADTH) does not
formally state a cost-effectiveness threshold for new medicines. A threshold of CAD $50,000 …

In recent years, novel cancer therapies have improved the expected survival of patients but
have also increased treatment costs. As a result of these increases, patients are concerned …

According to the consensus statement from the International Society for
Pharmacoeconomics and Outcomes Research Quality-Adjusted Life-Year (QALY) workshop …